(Q45367090)

English

Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis

scientific article published on 26 April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 December 2017

Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis (English)

1 reference

Europe PubMed Central

13 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Yu Xuan Koo

1

1 reference

Europe PubMed Central

13 December 2017

Matthew Tay

2

1 reference

Europe PubMed Central

13 December 2017

Yii Ean Teh

3

1 reference

Europe PubMed Central

13 December 2017

David Teng

4

1 reference

Europe PubMed Central

13 December 2017

Daniel S W Tan

5

1 reference

Europe PubMed Central

13 December 2017

Iain B H Tan

6

1 reference

Europe PubMed Central

13 December 2017

David W M Tai

7

1 reference

Europe PubMed Central

13 December 2017

Richard Quek

8

1 reference

Europe PubMed Central

13 December 2017

Miriam Tao

9

1 reference

Europe PubMed Central

13 December 2017

Soon Thye Lim

10

1 reference

Europe PubMed Central

13 December 2017

publication date

26 April 2011

1 reference

Europe PubMed Central

13 December 2017

Annals of Hematology

1 reference

Europe PubMed Central

13 December 2017

90

1 reference

Europe PubMed Central

13 December 2017

10

1 reference

Europe PubMed Central

13 December 2017

1219-1223

1 reference

Europe PubMed Central

13 December 2017

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1241-0

21 January 2018

Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1241-0

21 January 2018

Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1241-0

21 January 2018

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1241-0

21 January 2018

Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1241-0

21 January 2018

Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1241-0

21 January 2018

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1241-0

21 January 2018

Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1241-0

21 January 2018

How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1241-0

21 January 2018

Therapy of chronic hepatitis B: trends and developments

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1241-0

21 January 2018

Management of viral hepatitis in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1241-0

21 January 2018

Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1241-0

21 January 2018

RETRACTED: Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1200/JCO.2010.29.7531

Identifiers

10.1007/S00277-011-1241-0

1 reference

Europe PubMed Central

13 December 2017

1 reference

Europe PubMed Central

13 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45367090&oldid=2075895890"